(Q34313895)

1 August 2017

1 reference

title

Antipseudomonal penicillins (English)

1 reference

1 August 2017

2

File TM Jr

1 reference

1 August 2017

1

Tan JS

1 reference

1 August 2017

publication date

1 July 1995

1 reference

Medical Clinics of North America

1 August 2017

published in

1 reference

1 August 2017

volume

79

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

679-693

1 reference

Synergy of Carbenicillin and Gentamicin in Experimental Infection with Pseudomonas

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Combinations of antibiotics against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Beta-lactam antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Cross-resistance and imipenem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Antibiotic-induced release of endotoxin from bacteria in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Piperacillin versus cefotetan as single-dose prophylaxis in abdominal hysterectomy: a prospective, randomized, multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Combination effect of piperacillin with four aminoglycosides on nonfermenting gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Mezlocillin and azlocillin: an evaluation of two new β-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Platelet-mediated bleeding caused by broad-spectrum penicillins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Piperacillin, a new penicillin active against many bacteria resistant to other penicillins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Early synergistic interactions between amikacin and six beta-lactam antibiotics against multiply resistant members of the family Enterobacteriaceae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Resistance of Pseudomonas aeruginosa to new beta-lactamase-resistant beta-lactams

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Bacteriological antagonism between acylureidopenicillins and cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Severe Cholestatic Jaundice Caused by Mezlocillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Synergistic post-antibiotic effect of amikacin and beta-lactam antibiotics on Enterococcus faecalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Mezlocillin for treatment of infections in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Pharmacokinetics of piperacillin during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Antimicrobial agent therapy for Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

In vitro and in vivo antibacterial effects of combinations of beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Recurrent Paralysis Following Piperacillin Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Susceptibility of the Anaerobic Bacteria, Group D Streptococci, Enterobacteriaceae , and Pseudomonas to Semisynthetic Penicillins: Carbenicillin, Piperacillin, and Ticarcillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Sur

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Mezlocillin in the therapy of serious infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Ticarcillin for treatment of serious infections with gram-negative bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Synergy between cefotaxime, cefsulodin, azlocillin, mezlocillin and amino-glycosides against carbenicillin resistant or sensitive Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Resistance to Cefamandole: A Collaborative Study of Emerging Clinical Problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Piperacillin monotherapy compared with metronidazole and gentamicin combination in penetrating abdominal trauma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Comparison of bactericidal activity of selected beta-lactam antimicrobials against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Comparative therapy with cefpirome alone and in combination with rifampin and/or gentamicin against a disseminated Pseudomonas aeruginosa infection in leukopenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Potential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Effects of inoculum size on the activity of carboxy- and ureido-penicillins and effects of combinations of ureido-penicillins with aminoglycosides against resistant Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Comparative In Vitro Activity of Azlocillin, Ampicillin, Mezlocillin, Piperacillin, and Ticarcillin, Alone and in Combination with an Aminoglycoside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Piperacillin therapy for serious bacterial infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

The Efficacy of Mezlocillin-Amikacin Combination in Febrile Neutropenic Children with Oncologic Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Synergy of fluoroquinolones with other antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930032-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-7125(16)30032-3

0 references

1 reference